Clinical trial

CPT-SMART for Treatment of PTSD and Cigarette Smoking

Name
MHBB-008-18F
Description
Smoking is the leading cause of preventable illness, disability, and death in the United States. The rate of smoking is disproportionately higher among Veterans with posttraumatic stress disorder (PTSD). Unfortunately, smoking cessation efforts that are effective in the general population have shown limited effectiveness in smokers with PTSD. The high smoking rate and difficulty with achieving abstinence indicate a critical need to develop effective interventions for Veterans who smoke and have PTSD. The investigators' data indicate that negative emotions and trauma reminders are associated with relapse for smokers with PTSD. In this context, an ideal strategy may be to combine evidence-based PTSD treatment with intensive smoking cessation treatment to maximize quit rates. Cognitive processing therapy (CPT) is a well-established evidence-based treatment for PTSD. The investigators have successfully developed a treatment manual that combines CPT with cognitive-behavioral counseling for smoking cessation. Contingency management (CM) is another intensive behavioral treatment that has been shown to help with reducing smoking. CM provides positive reinforcers such as money to individuals misusing substances contingent upon abstinence from use. The primary goal of this study is to evaluate the efficacy of a treatment that combines CM with cognitive-behavioral smoking cessation counseling, smoking cessation medication, and CPT. Proposed is a randomized, two-arm clinical trial in which 120 Veteran smokers with PTSD will be randomized to either: 1) COGNITIVE PROCESSING THERAPY with SMOKING ABSTINENCE REINFORCEMENT THERAPY (CPT-SMART) or 2) COMBINED CONTACT CONTROL, an intervention identical to CPT-SMART in PTSD and smoking treatment, except for using payment that is not contingent on abstinence. Specific aims include: AIM 1) To evaluate the efficacy of CPT-SMART on rates of short- and long-term abstinence from cigarettes; AIM 2) To evaluate the impact of CPT-SMART on treatment engagement and utilization; and an EXPLORATORY AIM) To explore mechanisms of CPT-SMART on long-term smoking abstinence. The positive public health impact of reducing smoking among Veterans with PTSD could be enormous as it would prevent significant smoking-related morbidity and mortality.
Trial arms
Trial start
2019-11-07
Estimated PCD
2024-09-30
Trial end
2024-09-30
Status
Recruiting
Phase
Early phase I
Treatment
Smoking Cessation Cognitive Behavioral Therapy (CBT)
12 sessions of cognitive behavioral therapy for smoking cessation, designed to help participants prepare for quitting smoking, make a quit attempt, and stay quit from smoking.
Arms:
CPT-SMART, Combined Contact Yoked Control
Other names:
CBT
Bupropion
All medically eligible participants will be prescribed bupropion to begin 7 days before the quit date and continued through 12 weeks post-quit. Participants will be scheduled to begin at 150mg/day of bupropion for at least 3 days before titrating up to 300mg/day dose of bupropion.
Arms:
CPT-SMART, Combined Contact Yoked Control
Other names:
Zyban
Cognitive Processing Therapy
12 sessions of CPT, which is a well-established trauma-focused psychotherapy for PTSD that has demonstrated efficacy and effectiveness in Veterans.
Arms:
CPT-SMART, Combined Contact Yoked Control
Other names:
CPT
Smoking Abstinence Reinforcement Therapy
Monetary reinforcement for smoking abstinence that is bioverified by breath carbon monoxide and saliva samples.
Arms:
CPT-SMART
Other names:
SMART
Yoked Contingency Management
Participants in the yoked control will receive the monetary reinforcement of their yoked participant regardless of smoking abstinence or session attendance.
Arms:
Combined Contact Yoked Control
Other names:
Control CM
Size
120
Primary endpoint
Number of participants whose self-report of 7 day point prevalence abstinence from smoking is bioverified
6 month follow-up
Eligibility criteria
Inclusion Criteria: * Is Veteran * Is between the ages of 18 and 80 * Smokes ten or more cigarettes per day for the past year * Has been smoking for at least the past year * Meets criteria for current PTSD * Speaks and writes English * Is willing to attempt smoking cessation and trauma-focused psychotherapy Exclusion Criteria: * Has had myocardial infarction in the past 6 months * Uses other forms of nicotine that he/she is unwilling to stop * Is pregnant * Has a primary psychotic disorder * Has a current substance use disorder other than tobacco use disorder * Has a contraindication to bupropion use with no medical clearance to use it * Is unwilling to use bupropion * Is receiving other behavioral smoking counseling or trauma-focused therapy or plans to do so during the study period * Is currently imprisoned or in psychiatric hospitalization
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Randomized, two-arm clinical trial', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}}
Updated at
2024-04-19

1 organization

1 product

3 indications

Product
Bupropion
Indication
Post-Traumatic